Abstract
Stereotactic body radiotherapy (SBRT) for spinal metastases is very effective for pain relief and local tumor control. However, high-level evidence is limited to lesions in a single vertebra or in 2 contiguous vertebrae. To clarify the toxicities, we report herein the results of treatment for 4 patients who received SBRT to large-volume spinal tumors. The lesions comprised bone metastasis from renal cancer, local recurrence of rectal cancer invading the spine, osteosarcoma, and giant cell tumor of bone in 1 case each. Tumor volumes ranged from 738 to 1,766 ml. Doses ranging from 24 Gy in 2 fraction to 35 Gy in 5 fractions were delivered. The median follow-up was 24 months (range 4–35 months). Pain reduction was achieved in all patients in 4 weeks after SBRT. The outcomes were partial response in 1 patient, stable disease in 2, and tumor progression in 1. One patient showed grade 3 acute radiation dermatitis 4 weeks after SBRT, and another patient showed grade 3 late radiation dermatitis.
Similar content being viewed by others
References
Wang XS, Rhines LD, Shiu AS et al (2012) Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial. Lancet Oncol 13:395–402
Ryu S, Pugh SL, Gerszten PC et al (2011) RTOG 0631 phase II/III study of image-guided stereotactic radiosurgery for localized (1–3) spine metastases: phase II results. Int J Radiat Oncol Biol Phys 81:131–132
Lutz S, Berk L, Chang E et al (2011) Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 79:965–976
Thibault I, Campbell M, Tseng CL et al (2015) Salvage stereotactic body radiotherapy (SBRT) following in-field failure of initial SBRT for spinal metastases. Int J Radiation Oncol Biol Phys 93:353–360
McDonald R, Probyn L, Poon I et al (2015) tumor response after stereotactic body radiation therapy to non-spine bone metastases: an evaluation of response criteria. Int J Radiation Oncol Biol Phys 93:879–881
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Kanai T, Endo M, Minohara S et al (1999) Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys 44:201–210
Sahgal A, Weinberg V, Ma L et al (2013) Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice. Int J Radiat Oncol Biol Phys 85:341–347
Sahgal A, Atenafu EG, Chao S et al (2013) Spinal compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol 31:3426–3431
Cox BW, Jackson A, Hunt M et al (2012) Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 83:661–667
Fourney DR, Frangou EM, Ryken TC et al (2011) Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol 29:3072–3077
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there are no conflicts of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
About this article
Cite this article
Ito, K., Tanaka, H., Furuya, T. et al. First report of stereotactic body radiotherapy for large-volume spinal tumors. Int Canc Conf J 6, 149–153 (2017). https://doi.org/10.1007/s13691-017-0294-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-017-0294-x